BlepharitisPhase 4TBIDFTECWCTCNCT07451678
Treatment of Blepharitis Induced by Demodex Folliculorum Through Eyelid Cleansing With Wipes Containing Topical Chlorhexidine
A Phase 4 study testing Eyelid Cleansing with Wipes Containing Topical Chlorhexidine in people with Blepharitis, run by Instituto de Oftalmología Fundación Conde de Valenciana at 1 site in Mexico.
Trial summary
This study employed an experimental, prospective, longitudinal, before-and-after design to evaluate the efficacy of topical chlorhexidine wipes in treating blepharitis. The investigation focused on assessing signs and symptoms associated with Demodex Folliculorum blepharitis, including telangiectasia, ocular… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Blepharitis
- What is being tested?
- Eyelid Cleansing with Wipes Containing Topical Chlorhexidine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 39 participants
- Where
- 1 siteMexico
- Study dates
- 1 Jul 2024to 31 Jan 2025
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Clinical diagnosis of Demodex folliculorum blepharitis
- Presence of eyelash collarettes on slit-lamp examination
- Positive identification of Demodex folliculorum by epilation of 4 upper and 4 lower eyelashes per eyelid and visualization under light microscopy
- Willingness to use chlorhexidine eyelid wipes as instructed for 8 weeks
Who cannot join
- Use of topical or systemic antiparasitic treatment within the past 6 weeks
- Use of topical ophthalmic antibiotics or anti-inflammatory medication within the past 6 weeks
- Known allergy or hypersensitivity to chlorhexidine
- Pregnancy or breastfeeding
Trial locations and contacts
1 site in 1 country.
Mexico1 site
Instituto de Oftalmologia F.A.P. Conde de Valenciana, I.A.P.
Mexico City, Mexico City, 06800
About this study
This study employed an experimental, prospective, longitudinal, before-and-after design to evaluate the efficacy of topical chlorhexidine wipes in treating blepharitis.
The investigation focused on assessing signs and symptoms associated with Demodex Folliculorum blepharitis, including telangiectasia, ocular irritation, collarettes, foreign body sensation, tearing, eyelid erythema, and dry eye. Each subject underwent an assessment of the Demodex Folliculorum infection index through the epilation of four eyelashes, followed by direct visualization using optical microscopy. Additionally, the number of eyelashes with collarettes was categorized and graded as follows: Grade 0: 0-2 eyelashes per eyelid with collarettes; Grade 1: 3-10 eyelashes per eyelid with collarettes; Grade 2: ≥10 to ≤1/3; Grade 3: ≥1/3 - ≤2/3; Grade 4: ≥2/3 of eyelashes per eyelid with collarettes.
Participants applied topical chlorhexidine wipes twice daily, in the morning and evening, to cleanse the eyelash area of both eyelids over a period of four weeks. A follow-up assessment was conducted at four weeks, during which another Demodex test was performed to ascertain the presence of the microorganism. At week ten, the same signs and symptoms evaluated in the initial assessment were re-evaluated for follow-up.
- Conditions
- Blepharitis
- Being tested
- Eyelid Cleansing with Wipes Containing Topical Chlorhexidine
- Keywords
- Demodex, Blepharitis Drug Therapy, Anti-Infective Agents
- Medical subject headings
- Blepharitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Eyelid Cleansing with Wipes Containing Topical ChlorhexidineDrug
Participants applied topical chlorhexidine wipes twice daily, in the morning and evening, to cleanse the eyelash area of both eyelids over a period of four weeks. A follow-up assessment was conducted at four weeks, during which another Demodex test was performed to ascertain the presence of the microorganism. At week ten, the same signs and symptoms evaluated in the initial assessment were re-evaluated for follow-up.
| Study group | Role | What they receive |
|---|---|---|
| Treatment of Blepharitis by Demodex Folliculorum Group | Experimental | The investigation focused on assessing signs and symptoms associated with Demodex Folliculorum blepharitis, including telangiectasia, ocular irritation, collarettes, foreign body sensation, tearing, eyelid erythema, and dry eye. Receives: Drug: Eyelid Cleansing with Wipes Containing Topical Chlorhexidine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reduction in Demodex folliculorum count per eyelash
Mean number of Demodex folliculorum mites per eyelash (mites/lash) assessed by epilation of 4 eyelashes from the upper eyelid and 4 eyelashes from the lower eyelid and examination under light microscopy at 40× magnification. The outcome will be reported as the change in mean mites/lash from baseline to 8 weeks after treatment with chlorhexidine eyelid wipes.
Measured: Baseline and 8 weeks
Secondary outcomes (2)
Change in eyelash collarette grade
Proportion of eyelashes with collarettes per eyelid assessed by slit-lamp examination and graded using a standardized 0-4 scale:
Grade 0: 0-2 lashes; Grade 1: 3-10 lashes; Grade 2: >10 lashes to ≤1/3 of lashes; Grade 3: >1/3 to ≤2/3 of lashes; Grade 4: >2/3 of lashes per eyelid. The outcome will be reported as change in grade from baseline to 8 weeks.
Measured: Baseline and 8 weeks
Proportion of participants by Ocular Surface Disease Index (OSDI) severity category
Proportion of participants classified according to Ocular Surface Disease Index (OSDI) severity category based on the validated 12-item OSDI questionnaire (0-100 scale). Severity categories will be defined as:
Normal (0-12), Mild (13-22), Moderate (23-32), and Severe (33-100). The outcome will be expressed as the percentage of participants in each severity category at baseline and at 8 weeks after treatment with chlorhexidine eyelid wipes.
Measured: Baseline and 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Mar 2026
- Study start1 Jul 2024
- Primary completion1 Aug 2024
- Study completion31 Jan 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (18)Papers the sponsor has linked to this study.
- Other trials for BlepharitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 39 participants (actual)
Sponsor and investigators
- Lead sponsor
- Instituto de Oftalmología Fundación Conde de Valenciana
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07451678
- Sponsor's protocol ID
- CEI-2024/06/07
- Acronym
- TBIDFTECWCTC
- Status last verified
- Jul 2026
- First submitted
- 8 Feb 2026
- Last updated
- 8 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Steinsapir KD, Woodward JA. Chlorhexidine Keratitis: Safety of Chlorhexidine as a Facial Antiseptic. Dermatol Surg. 2017 Jan;43(1):1-6. doi: 10.1097/DSS.0000000000000822.
PubMed 27399954Cheng SN, Jiang FG, Chen H, Gao H, Huang YK. Intense Pulsed Light Therapy for Patients with Meibomian Gland Dysfunction and Ocular Demodex Infestation. Curr Med Sci. 2019 Oct;39(5):800-809. doi: 10.1007/s11596-019-2108-1. Epub 2019 Oct 14.
PubMed 31612399Gaddie IB, Donnenfeld ED, Karpecki P, Vollmer P, Berdy GJ, Peterson JD, Simmons B, Edell ARP, Whitson WE, Ciolino JB, Baba SN, Holdbrook M, Trevejo J, Meyer J, Yeu E; Saturn-2 Study Group. Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2). Ophthalmology. 2023 Oct;130(10):1015-1023. doi: 10.1016/j.ophtha.2023.05.030. Epub 2023 Jun 5.
PubMed 37285925Yeu E, Wirta DL, Karpecki P, Baba SN, Holdbrook M; Saturn I Study Group. Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1). Cornea. 2023 Apr 1;42(4):435-443. doi: 10.1097/ICO.0000000000003097. Epub 2022 Aug 10.
PubMed 35965392Cheung IMY, Xue AL, Kim A, Ammundsen K, Wang MTM, Craig JP. In vitro anti-demodectic effects and terpinen-4-ol content of commercial eyelid cleansers. Cont Lens Anterior Eye. 2018 Dec;41(6):513-517. doi: 10.1016/j.clae.2018.08.003. Epub 2018 Aug 14.
PubMed 30120003Savla K, Le JT, Pucker AD. Tea tree oil for Demodex blepharitis. Cochrane Database Syst Rev. 2020 Jun 20;6(6):CD013333. doi: 10.1002/14651858.CD013333.pub2.
PubMed 32589270Martinez-Pulgarin DF, Avila MY, Rodriguez-Morales AJ. Interventions for Demodex blepharitis and their effectiveness: A systematic review and meta-analysis. Cont Lens Anterior Eye. 2021 Dec;44(6):101453. doi: 10.1016/j.clae.2021.101453. Epub 2021 May 7.
PubMed 33972176Farid M, Ayres BD, Donnenfeld E, Gaddie IB, Gupta PK, Holland E, Lindstrom R, Pflugfelder SC, Karpecki PM, Nichols KK, Starr CE, Yeu E. Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis. Clin Ophthalmol. 2023 Feb 27;17:667-679. doi: 10.2147/OPTH.S399989. eCollection 2023.
PubMed 36875531Rhee MK, Yeu E, Barnett M, Rapuano CJ, Dhaliwal DK, Nichols KK, Karpecki P, Mah FS, Chan A, Mun J, Gaddie IB. Demodex Blepharitis: A Comprehensive Review of the Disease, Current Management, and Emerging Therapies. Eye Contact Lens. 2023 Aug 1;49(8):311-318. doi: 10.1097/ICL.0000000000001003. Epub 2023 Jun 2.
PubMed 37272680Hirsch-Hoffmann S, Kaufmann C, Banninger PB, Thiel MA. Treatment options for demodex blepharitis: patient choice and efficacy. Klin Monbl Augenheilkd. 2015 Apr;232(4):384-7. doi: 10.1055/s-0035-1545780. Epub 2015 Apr 22.
PubMed 25902082Shah PP, Stein RL, Perry HD. Update on the Management of Demodex Blepharitis. Cornea. 2022 Aug 1;41(8):934-939. doi: 10.1097/ICO.0000000000002911. Epub 2021 Nov 3.
PubMed 34743107Muntz A, Purslow C, Wolffsohn JS, Craig JP. Improved Demodex diagnosis in the clinical setting using a novel in situ technique. Cont Lens Anterior Eye. 2020 Aug;43(4):345-349. doi: 10.1016/j.clae.2019.11.009. Epub 2019 Dec 3.
PubMed 31806355Hom MM, Mastrota KM, Schachter SE. Demodex. Optom Vis Sci. 2013 Jul;90(7):e198-205. doi: 10.1097/OPX.0b013e3182968c77.
PubMed 23748846Luo X, Li J, Chen C, Tseng S, Liang L. Ocular Demodicosis as a Potential Cause of Ocular Surface Inflammation. Cornea. 2017 Nov;36 Suppl 1(Suppl 1):S9-S14. doi: 10.1097/ICO.0000000000001361.
PubMed 28902017Murphy O, O' Dwyer V, Lloyd-McKernan A. The Clinical Use of Eyelash Manipulation in the Diagnosis of Demodex folliculorum Blepharitis. Eye Contact Lens. 2020 Jan;46 Suppl 1:S33-S38. doi: 10.1097/ICL.0000000000000608.
PubMed 30950926
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Treatment of Blepharitis Induced by Demodex Folliculorum Through Eyelid Cleansing With Wipes Containing Topical Chlorhexidine
- ClinicalTrials.gov ID
- NCT07451678
- Acronym / sponsor ID
- TBIDFTECWCTC / CEI-2024/06/07
- Conditions
- Blepharitis
- Keywords
- Demodex, Blepharitis Drug Therapy, Anti-Infective Agents
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 39 participants (actual)
- Lead sponsor
- Instituto de Oftalmología Fundación Conde de ValencianaUniversity, hospital or other
- Study start
- 1 Jul 2024 (actual)
- Primary completion
- 1 Aug 2024 (actual)
- Study completion
- 31 Jan 2025 (actual)
- First posted
- 5 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study employed an experimental, prospective, longitudinal, before-and-after design to evaluate the efficacy of topical chlorhexidine wipes in treating blepharitis.
The investigation focused on assessing signs and symptoms associated with Demodex Folliculorum blepharitis, including telangiectasia, ocular irritation, collarettes, foreign body sensation, tearing, eyelid erythema, and dry eye. Each subject underwent an assessment of the Demodex Folliculorum infection index through the epilation of four eyelashes, followed by direct visualization using optical microscopy. Additionally, the number of eyelashes with collarettes was categorized and graded as follows: Grade 0: 0-2 eyelashes per eyelid with collarettes; Grade 1: 3-10 eyelashes per eyelid with collarettes; Grade 2: ≥10 to ≤1/3; Grade 3: ≥1/3 - ≤2/3; Grade 4: ≥2/3 of eyelashes per eyelid with collarettes.
Participants applied topical chlorhexidine wipes twice daily, in the morning and evening, to cleanse the eyelash area of both eyelids over a period of four weeks. A follow-up assessment was conducted at four weeks, during which another Demodex test was performed to ascertain the presence of the microorganism. At week ten, the same signs and symptoms evaluated in the initial assessment were re-evaluated for follow-up.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Treatment of Blepharitis by Demodex Folliculorum Group | Experimental | Drug: Eyelid Cleansing with Wipes Containing Topical ChlorhexidineThe investigation focused on assessing signs and symptoms associated with Demodex Folliculorum blepharitis, including telangiectasia, ocular irritation, collarettes, foreign body sensation, tearing, eyelid erythema, and dry eye. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age ≥ 18 years
- Clinical diagnosis of Demodex folliculorum blepharitis
- Presence of eyelash collarettes on slit-lamp examination
- Positive identification of Demodex folliculorum by epilation of 4 upper and 4 lower eyelashes per eyelid and visualization under light microscopy
- Willingness to use chlorhexidine eyelid wipes as instructed for 8 weeks
Key exclusion criteria (4 listed)
- Use of topical or systemic antiparasitic treatment within the past 6 weeks
- Use of topical ophthalmic antibiotics or anti-inflammatory medication within the past 6 weeks
- Known allergy or hypersensitivity to chlorhexidine
- Pregnancy or breastfeeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Eyelid Cleansing with Wipes Containing Topical ChlorhexidineParticipants applied topical chlorhexidine wipes twice daily, in the morning and evening, to cleanse the eyelash area of both eyelids over a period of four weeks. A follow-up assessment was conducted at four weeks, during which another Demodex test was performed to ascertain the presence of the microorganism. At week ten, the same signs and symptoms evaluated in the initial assessment were re-evaluated for follow-up. | Drug | Treatment of Blepharitis by Demodex Folliculorum Group |
Primary outcome
Reduction in Demodex folliculorum count per eyelash
Time frame: Baseline and 8 weeks
Mean number of Demodex folliculorum mites per eyelash (mites/lash) assessed by epilation of 4 eyelashes from the upper eyelid and 4 eyelashes from the lower eyelid and examination under light microscopy at 40× magnification. The outcome will be reported as the change in mean mites/lash from baseline to 8 weeks after treatment with chlorhexidine eyelid wipes.
2 secondary outcomes
Change in eyelash collarette grade
Time frame: Baseline and 8 weeks
Proportion of participants by Ocular Surface Disease Index (OSDI) severity category
Time frame: Baseline and 8 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2026.
- Results publication: PubMed 27399954Steinsapir KD, Woodward JA. Chlorhexidine Keratitis: Safety of Chlorhexidine as a Facial Antiseptic. Dermatol Surg. 2017 Jan;43(1):1-6. doi: 10.1097/DSS.0000000000000822.
- Results publication: PubMed 31612399Cheng SN, Jiang FG, Chen H, Gao H, Huang YK. Intense Pulsed Light Therapy for Patients with Meibomian Gland Dysfunction and Ocular Demodex Infestation. Curr Med Sci. 2019 Oct;39(5):800-809. doi: 10.1007/s11596-019-2108-1. Epub 2019 Oct 14.
- Results publication: PubMed 37285925Gaddie IB, Donnenfeld ED, Karpecki P, Vollmer P, Berdy GJ, Peterson JD, Simmons B, Edell ARP, Whitson WE, Ciolino JB, Baba SN, Holdbrook M, Trevejo J, Meyer J, Yeu E; Saturn-2 Study Group. Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2). Ophthalmology. 2023 Oct;130(10):1015-1023. doi: 10.1016/j.ophtha.2023.05.030. Epub 2023 Jun 5.
- Results publication: PubMed 35965392Yeu E, Wirta DL, Karpecki P, Baba SN, Holdbrook M; Saturn I Study Group. Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1). Cornea. 2023 Apr 1;42(4):435-443. doi: 10.1097/ICO.0000000000003097. Epub 2022 Aug 10.
- Results publication: PubMed 30120003Cheung IMY, Xue AL, Kim A, Ammundsen K, Wang MTM, Craig JP. In vitro anti-demodectic effects and terpinen-4-ol content of commercial eyelid cleansers. Cont Lens Anterior Eye. 2018 Dec;41(6):513-517. doi: 10.1016/j.clae.2018.08.003. Epub 2018 Aug 14.
- Results publication: PubMed 32589270Savla K, Le JT, Pucker AD. Tea tree oil for Demodex blepharitis. Cochrane Database Syst Rev. 2020 Jun 20;6(6):CD013333. doi: 10.1002/14651858.CD013333.pub2.
- Results publication: PubMed 33972176Martinez-Pulgarin DF, Avila MY, Rodriguez-Morales AJ. Interventions for Demodex blepharitis and their effectiveness: A systematic review and meta-analysis. Cont Lens Anterior Eye. 2021 Dec;44(6):101453. doi: 10.1016/j.clae.2021.101453. Epub 2021 May 7.
- Results publication: PubMed 36875531Farid M, Ayres BD, Donnenfeld E, Gaddie IB, Gupta PK, Holland E, Lindstrom R, Pflugfelder SC, Karpecki PM, Nichols KK, Starr CE, Yeu E. Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis. Clin Ophthalmol. 2023 Feb 27;17:667-679. doi: 10.2147/OPTH.S399989. eCollection 2023.
- Results publication: PubMed 37272680Rhee MK, Yeu E, Barnett M, Rapuano CJ, Dhaliwal DK, Nichols KK, Karpecki P, Mah FS, Chan A, Mun J, Gaddie IB. Demodex Blepharitis: A Comprehensive Review of the Disease, Current Management, and Emerging Therapies. Eye Contact Lens. 2023 Aug 1;49(8):311-318. doi: 10.1097/ICL.0000000000001003. Epub 2023 Jun 2.
- Results publication: PubMed 25902082Hirsch-Hoffmann S, Kaufmann C, Banninger PB, Thiel MA. Treatment options for demodex blepharitis: patient choice and efficacy. Klin Monbl Augenheilkd. 2015 Apr;232(4):384-7. doi: 10.1055/s-0035-1545780. Epub 2015 Apr 22.
- Results publication: PubMed 34743107Shah PP, Stein RL, Perry HD. Update on the Management of Demodex Blepharitis. Cornea. 2022 Aug 1;41(8):934-939. doi: 10.1097/ICO.0000000000002911. Epub 2021 Nov 3.
- Results publication: PubMed 31806355Muntz A, Purslow C, Wolffsohn JS, Craig JP. Improved Demodex diagnosis in the clinical setting using a novel in situ technique. Cont Lens Anterior Eye. 2020 Aug;43(4):345-349. doi: 10.1016/j.clae.2019.11.009. Epub 2019 Dec 3.
- Individual participant dataSharing planned: Yes
Related trials for Blepharitis
Not yet recruitingPhase 2
A Phase 2 Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis
Blepharitis
RecruitingObservational study
Ocular Dysbiosis in Eyelid Disease
Anterior Blepharitis
Not yet recruitingPhase 4
Clinical Lid Eradication of Antifungal-Responsive FUNGUS Study
Anterior Blepharitis
RecruitingObservational study
Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the Eye
Artifical Intelligence, Cataract
RecruitingPhase 2
Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
Demodex Blepharitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Eyelid Cleansing with Wipes Containing Topical Chlorhexidine in people with Blepharitis, run by Instituto de Oftalmología Fundación Conde de Valenciana at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reduction in Demodex folliculorum count per eyelash (time frame: Baseline and 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07451678, which also lists 18 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2026.